AstraZeneca’s (AZN) Lynparza significantly delayed the recurrence of tumors in patients with ovarian cancer compared to a placebo, according to results from a phase III study announced by the company Wednesday.
Lynparza belongs to a closely followed class of cancer drugs known as PARP inhibitors. Wednesday’s positive study results, if confirmed, position Lynparza for expanded U.S. approval as a maintenance therapy in ovarian cancer.
